Grace Therapeutics, Inc. · NASDAQ:GRCE

Grace Therapeutics, Inc. financial statements

Grace Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue0000100.0M196.0K
Cost of revenue7.00K7.00K11.0K124.0K076.0K3.12M2.68M2.57M
Gross profit-7.00K-7.00K-11.0K-124.0K0189.4K-3.12M-2.68M-2.57M
Research and development2.40M9.51M4.68M9.97M5.56M4.17M16.0M29.4M12.1M7.18M
Selling, general and administrative8.66M10.2M9.02M10.9M12.1M8.70M11.6M3.80M3.12M
Operating income-11.1M-16.7M-12.9M-52.2M-15.6M-16.4M-24.4M-34.4M-15.3M-10.5M
Depreciation and amortization7.00K7.00K11.0K124.0K0143.0K410.0K384.0K2.07M2.57M
EBITDA-11.1M-16.7M-12.8M-52.0M-15.6M-16.3M-24.0M-34.0M-13.2M-7.95M
Interest expense331.6K414.2K1.05M371.6K54.4K
Income before tax-9.49M-12.8M-14.7M-52.0M-10.5M-19.7M-25.5M-39.4M-16.7M-10.7M
Income tax-1.70M-3.20M-1.83M-9.54M-648.0K000-121.1K
Net income-7.79M-9.57M-12.9M-42.4M-9.82M-19.7M-25.5M-39.4M-16.7M-10.6M
Earnings per share, basic-0.47-0.79-1.35-5.71-0.27-1.33-0.30-0.73-45.71-45.67
Earnings per share, diluted-0.47-0.79-1.35-5.71-0.27-1.33-0.30-0.73

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents17.0M22.1M23.0M27.9M30.3M50.9M14.2M16.9M6.37M
Short-term investments015.0K13.3M9.79M9.79M8.89M
Receivables20.0K126.0K722.0K802.0K548.0K530.0K546.0K1.19M759.3K206.2K
Inventory1
Current assets17.4M22.7M24.0M29.3M45.3M62.4M18.5M28.0M7.35M10.2M
Property, plant and equipment8.00K15.0K24.0K104.0K20.9M1.91M2.11M
Goodwill8.14M8.14M8.14M8.14M13.0M0
Total assets66.7M72.0M73.3M79.1M128.6M62.5M22.9M36.9M17.8M25.5M
Accounts payable702.0K601.0K1.01M1.24M3.16M144.5K2.42M3.05M2.65M
Current liabilities2.15M1.93M1.68M3.41M3.26M1.58M7.39M13.7M5.19M2.14M
Total debt485.0K295.0K108.0K207.8K1.36M1.25M1.41M
Total liabilities2.76M5.38M11.6M11.2M20.4M6.80M9.86M25.9M11.4M3.76M
Shareholders' equity63.9M66.6M61.7M68.0M108.3M55.7M13.0M11.0M6.37M21.7M
Shares outstanding16.0M13.7M9.40M7.44M44.3M44.6M44.4M208.4M364.3K231.1K

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-8.87M-14.9M-12.3M-15.9M-17.2M-14.3M-23.0M-24.8M-9.69M-6.94M
Capital spending00-22.0K-17.0K0-86.7K-450.9K-534.0K-352.3K-2.57M
Free cash flow-8.87M-14.9M-12.4M-15.9M-17.2M-18.1M-32.9M-25.3M-10.0M-9.51M
Cash from investing00104.0K13.2M-3.52M-9.86M8.14M-9.44M-318.3K6.85M
Cash from financing3.71M14.0M7.36M304.0K059.5M13.2M45.7M8.83M7.00M
Share buybacks-31.0K
Change in cash-5.16M-872.0K-4.87M-2.46M-20.6M36.7M-2.63M10.4M-1.20M-2.98M